Jaguar Animal Health Inc (JAGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.59M
Last updated: Nov 17, 2026 at 11:05 AM ET
Jaguar Animal Health Inc (JAGX) Earnings: Report Dates and Results
Jaguar Animal Health (JAGX) is expected to report earnings on Apr 5, 2027. In the quarter ended Jun 30, 2026, Jaguar Animal Health reported EPS of -$15.70, above the -$52.15 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
JAGX has an expected report date of Apr 5, 2027.
JAGX Earnings Call
The latest JAGX earnings call transcript on file is labeled 2025Q2.
Read the 2025Q2 transcriptEarnings History
Of the 37 quarters below that had an estimate, JAGX beat 16, missed 15 and matched 6. Revenue for the quarter ended Jun 30, 2026 was $1.23M, down 58.7% from $2.98M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$15.70 | -$52.15 | N/A | +69.89% | Beat | N/A | N/A | N/A | Aug 19, 2026 | $1.23M |
| Sep 30, 2025 | -$219.80 | -$177.80 | N/A | -23.62% | Miss | N/A | 1 | 1 up, 0 down | Nov 14, 2025 | $3.08M |
| Jun 30, 2025 | -$259.26 | -$249.55 | N/A | -3.89% | Miss | N/A | 1 | 1 up, 0 down | Aug 14, 2025 | $2.98M |
| Mar 31, 2025 | -$16.70 | -$10.82 | -$10.82 - -$10.82 | -54.34% | Miss | N/A | 1 | 1 up, 0 down | May 15, 2025 | $2.21M |
| Dec 31, 2024 | -$4,403.00 | -$647.50 | N/A | -580.00% | Miss | N/A | 1 | 1 up, 0 down | Mar 31, 2025 | $3.51M |
| Sep 30, 2024 | -$918.75 | -$2,073.75 | N/A | +55.70% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2024 | $3.11M |
| Jun 30, 2024 | -$3,535.00 | -$1,050.00 | N/A | -236.67% | Miss | N/A | 1 | 0 up, 0 down | Aug 12, 2024 | $2.72M |
| Mar 31, 2024 | -$3,459.75 | -$1,575.00 | N/A | -119.67% | Miss | N/A | 1 | 0 up, 0 down | Apr 1, 2024 | $2.35M |
| Dec 31, 2023 | -$33.00 | -$73.80 | N/A | +55.28% | Beat | N/A | N/A | 0 up, 0 down | Jan 31, 2024 | $2.30M |
| Sep 30, 2023 | -$19,949.98 | -$64,574.94 | N/A | +69.11% | Beat | N/A | N/A | 0 up, 0 down | Nov 13, 2023 | $2.81M |
| Jun 30, 2023 | -$36,224.96 | -$80,324.92 | N/A | +54.90% | Beat | N/A | N/A | N/A | Aug 13, 2023 | $2.68M |
| Mar 31, 2023 | -$125,474.87 | -$236,250.35 | N/A | +46.89% | Beat | N/A | N/A | 0 up, 0 down | May 15, 2023 | $1.97M |
| Dec 31, 2022 | -$3.43 | -$9.75 | N/A | +64.82% | Beat | N/A | N/A | 0 up, 0 down | Mar 27, 2023 | $3.26M |
| Sep 30, 2022 | -$472,500.71 | -$275,625.41 | -$314,844.31 - -$275,488.77 | -71.43% | Miss | N/A | 2 | 0 up, 0 down | Nov 14, 2022 | $3.15M |
| Jun 30, 2022 | -$472,500.71 | -$748,126.12 | N/A | +36.84% | Beat | N/A | 1 | 0 up, 0 down | Aug 22, 2022 | $2.92M |
| Mar 31, 2022 | -$1,000,000.00 | -$708,751.06 | N/A | -41.09% | Miss | N/A | 2 | 0 up, 0 down | May 10, 2022 | $2.63M |
| Dec 31, 2021 | -$23.25 | -$6.75 | -$7.52 - -$6.02 | -244.44% | Miss | N/A | 2 | N/A | Mar 11, 2022 | $2.08M |
| Sep 30, 2021 | -$1,000,000.00 | -$787,501.18 | N/A | -26.98% | Miss | N/A | 2 | N/A | Nov 17, 2021 | $630000 |
| Jun 30, 2021 | -$1,000,000.00 | -$1,063,233.03 | N/A | +5.95% | Beat | N/A | 2 | N/A | Aug 13, 2021 | $385000 |
| Mar 31, 2021 | -$1,000,000.00 | -$236,250.38 | N/A | -323.28% | Miss | N/A | 1 | N/A | May 17, 2021 | $1.24M |
| Dec 31, 2020 | -$33.75 | -$22.50 | N/A | -50.00% | Miss | N/A | 1 | N/A | Mar 31, 2021 | $6.22M |
| Sep 30, 2020 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 1 | N/A | Nov 16, 2020 | N/A |
| Jun 30, 2020 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 2 | N/A | Aug 13, 2020 | $3.17M |
| Mar 31, 2020 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 2 | N/A | Apr 3, 2020 | N/A |
| Sep 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 2 | N/A | Nov 14, 2019 | $973000 |
| Jun 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | -1428571528.4% | 1 | N/A | Aug 14, 2019 | $1.71M |
| Mar 31, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Apr 10, 2019 | $1.59M |
| Dec 31, 2018 | -$0.38 | -$0.07 | N/A | -435.71% | Miss | -635.7% | N/A | N/A | Mar 13, 2019 | $1.60M |
| Sep 30, 2018 | -$0.51 | -$0.45 | N/A | -13.33% | Miss | N/A | N/A | N/A | Nov 19, 2018 | $1.13M |
| Jun 30, 2018 | $0.07 | -$0.45 | N/A | +115.56% | Beat | N/A | N/A | N/A | Aug 13, 2018 | $883846 |
| Mar 31, 2018 | -$52.50 | -$0.60 | N/A | N/A | N/A | N/A | N/A | N/A | Apr 9, 2018 | $804356 |
| Dec 31, 2017 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 14, 2018 | $1.54M |
| Sep 30, 2017 | -$63.00 | -$136.50 | N/A | +53.85% | Beat | N/A | N/A | N/A | Nov 20, 2017 | $1.10M |
| Jun 30, 2017 | -$126.00 | -$231.00 | N/A | +45.45% | Beat | N/A | N/A | N/A | Aug 9, 2017 | $896521 |
| Mar 31, 2017 | -$5.00 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2017 | $822410 |
| Dec 31, 2016 | -$294.00 | -$252.00 | N/A | -16.67% | Miss | N/A | N/A | N/A | Feb 15, 2017 | $28877 |
| Sep 30, 2016 | -$315.00 | -$420.00 | N/A | +25.00% | Beat | N/A | N/A | N/A | Nov 14, 2016 | $50357 |
| Jun 30, 2016 | -$367.50 | -$404.25 | N/A | +9.09% | Beat | N/A | N/A | N/A | Aug 15, 2016 | $24143 |
| Mar 31, 2016 | -$451.50 | -$514.50 | N/A | +12.24% | Beat | N/A | N/A | N/A | May 10, 2016 | $38146 |
| Dec 31, 2015 | -$441.00 | -$677.25 | N/A | +34.88% | Beat | N/A | N/A | N/A | Mar 29, 2016 | $55186 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2024 was -$12,316.50, after -$181,682.81 the year before. It was -$1,871.19 for the year ended Dec 31, 2015, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2024 | -$12,316.50 | N/A |
| Dec 31, 2023 | -$181,682.81 | N/A |
| Dec 31, 2022 | -$1,945,004.85 | N/A |
| Dec 31, 2021 | -$3,000,023.25 | N/A |
| Dec 31, 2020 | -$6,000,033.75 | N/A |
| Dec 31, 2018 | -$53.32 | N/A |
| Dec 31, 2017 | -$193.93 | N/A |
| Dec 31, 2016 | -$1,428.00 | N/A |
| Dec 31, 2015 | -$1,871.19 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2025Q2 for the period ended Jun 30, 2025, runs about 3,400 words across 3 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q2 | Jun 30, 2025 | 3,421 | 3 | |
| 2025Q1 | Mar 31, 2025 | 2,866 | 4 | |
| 2024Q3 | Sep 30, 2024 | 5,283 | 4 | |
| 2024Q2 | Jun 30, 2024 | 5,731 | 5 |
2025Q2 Earnings Call
Opening remarks
Lisa A. Conte CEO Thank you very much. Thank you for those introductory statements. Hello. Thank you for joining our webcast today. As you heard, my name is Lisa Conte. I am the Founder, President and CEO of Jaguar Health and our wholly owned subsidiary, Napo Pharmaceuticals. And I'm the Chairman of our Italian subsidiary, Napo Therapeutics. So as usual, if you've been on these webcasts before, I may use the words Jaguar and Napo interchangeably to refer to our company and our company activities. So as announced, this is an earnings webcast. And after I speak, our CFO, Carol Lizak, will provide a recap of the financial highlights for the second quarter of 2025. And as in the past, I am going to steal the thunder of Carol as we're pleased to report that our combined net second quarter 2025 revenue of approximately $3 million for prescription and nonprescription products, including license revenue, increased approximately 35% versus net Q1 2025, and it increased approximately 10% versus net Q2 2024. We're quite pleased with that. And to move along to the bigger picture for the company, 2025 continues to be the year of convergence of key clinical and regulatory catalysts for Jaguar. Catalysts that we feel will be transformative in terms of the value they bring to all the stakeholders in the company from patients, first and foremost, to our shareholders. Simply put, with the recent achievement of these catalysts, our strategy is to seek, and we are seeking business development partnerships for licensed rights to the development and commercialization of Jaguar's Human and Animal Health products with the goal of generating nondilutive funding for Jaguar. So important at this time of pullback and hopefully, temporary pullback of investor support for innovations in emerging pharma companies well beyond what we're seeing here at Jaguar. These catalysts are the key to those deals. To recap our recent catalysts, and may I comment that these remarkable, groundbreaking results are the culmination of years of regulatory and clinical planning activities and implementation, in some cases, up to eight years. And it just so happens that we have a convergence of critical catalysts at this time, again, in support of the opportunities for really important business development deals. On April 30 of this year, we released initial results from an independent investigator-initiated proof-of-concept study in pediatric patients in Abu Dhabi of a novel liquid formulation of crofelemer, our first-in-class plant-based paradigm-shifting prescription drug for intestinal failure associated with what we call microvillus inclusion disease, or MVID, which is an ultra-rare disease. And also intestinal failure associated with short bowel syndrome, SBS. For both these indications, crofelemer has orphan drug designation in the U.S.
Frequently Asked Questions About JAGX
When is Jaguar Animal Health's next earnings date?
Jaguar Animal Health's next earnings report is expected for Apr 5, 2027.
Did JAGX beat earnings estimates last quarter?
Yes. Jaguar Animal Health reported EPS of -$15.70 for the quarter ended Jun 30, 2026, above the -$52.15 estimate, a 69.89% surprise.
How often does JAGX beat earnings estimates?
Jaguar Animal Health beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -111.57%.
JAGX pages: Overview, Earnings, Forecast, Financials, Competitors